Rheumatoid Arthritis

CDAI remission does not describe every symptom. In a 787-patient RA study, those in remission still had meaningful pain interference (19%), fatigue (20%) and impaired function (23%). PROMIS scores show symptoms that composite score missed. #2874 @Rheumnow #ACR26

In 8,090 RApts 18.3% had unacceptable pain and 14.6% had patient-physician discordance ≥3 cm. #ACR26 Abstract 0617: discordance was the strongest correlate of unacceptable pain, followed by joint distribution and disability. Ask why pain and inflammation disagree. @RheumNow https://t.co/8zVt1fo30J

https://x.com/bella_mehta/status/2120230013353988549/photo/1

Can genetics sharpen the search for silent RA-ILD? #ACR26: In 186 RA patients, 21% had subclinical ILD on HRCT. Clinical screening achieved an AUC of 0.713; adding MUC5B improved it only modestly to 0.739. Genetics adds risk, but limited discrimination. @RheumNow #ACR26 https://t.co/WjK8TFP45m

https://x.com/Mota_licia_reum/status/2120228504071528543/photo/1

Can adverse pregnancy outcomes predict SLE or RA? Abstract 2860 found: - Future SLE assoc. w/ hx of preeclampsia (aOR 1.89), emergency c-section (aOR 1.90), and short gestational duration (aOR 0.93) - Future RA assoc w high pre-pregnancy BMI (aOR 1.19) @RheumNow #ACR26

Which patient with ICI joint disease will have persistent disease? Risk factors include: - tenosynovitis on US/MRI - elevated CRP - baseline GC use - age <65 - peripheral inflam arthritis pattern @RheumNow #ACR26 Abst2806

RA Treatment: A New Nerve Pathway #ACR26 Abstract 1426 | RESET-RA: 242 patients with prior b/tsDMARD failure. At 24 months, vagus nerve stimulation achieved ACR20/50/70 rates of 70.9%/43.6%/25.5%, with ~55% reaching LDA/remission, without add-on therapy. @RheumNow https://t.co/ko6jvXcoRc

https://x.com/Mota_licia_reum/status/2120225588598157717/photo/1

Is air pollution linked to higher arthritis activity? Abstract 2859 found: - PM10, PM2.5 & NO2 each tracked with higher CDAI & DAPSA - every 1-quartile incr. in all together associated with higher: • DAS28 (RA/SpA) +0.06 • CDAI (RA) +1.46 • DAPSA (PsA) +1.60 #ACR26 @RheumNow https://t.co/iIHfCMbn3P

https://x.com/AkhilSoodMD/status/2120224218553983343/photo/1

2 Weeks off Methotrexate Boosts Zoster Response Consider holding methotrexate for two weeks after each recombinant zoster vaccine dose when disease is stable, and give the vaccine before rituximab when timing allows. Those are the messages from a pair of abstracts presented by https://t.co/qeEQp0LeHB

Jamshaid & Gomaa (Tirzepatide vs semaglutide cohort): Tirzepatide vs semaglutide in inflammatory arthritis: steroid use at 1 year was 19.1% vs 22.5% in matched cohorts. @rheumnow #ACR2026 Abstract#2641

Weber et al. (TOGETHER PsO&PsA): 30% lower predicted 10-year CVD risk vs pts IXE mono. suggest that targeting both inflammatory and metabolic pathways may improve CV benefit and potentially reduce long-term CV burden in this high-risk population. @rheumnow #ACR2026 Abstract#2299

Weber et al. (TOGETHER cardiometabolic analysis): ixekizumab + tirzepatide was associated with about 30% lower predicted 10-year CV risk vs ixekizumab alone at week 36. @rheumnow #ACR2026 Abstract#2299 https://t.co/NmulNKUwLL

https://x.com/Gibson_RheumPAC/status/2120207359179948201/photo/1

Jamshaid et al: Tirzepatide vs semaglutide in inflammatory arthritis: 3-year steroid use was 27.2% vs 37.5%. Less treatment escalation is intriguing. @rheumnow #ACR2026 #ACRBest Abstract#2641

Which patients with started on GC are at increased risk of metabolic AEs? Abstract 2754 found that baseline - CHF (OR 3.21) > CKD (OR 1.86) strongest predictors - MTX use lowered risk (OR 0.68) @RheumNow #ACR26 https://t.co/ZLWCcypf4W

https://x.com/AkhilSoodMD/status/2120198045945966654/photo/1

Inflammation may improve while pain persists in SLE. #ACR26 Abstract 2824: in 372 pts, 37% had mixed inflammatory + nociplastic symptoms. Over follow-up, inflammation declined but polysymptomatic distress stayed flat; ~37% remained above the nociplastic threshold. @RheumNow

Access matters. Among 16381 Canadian adults with RMDs and diabetes starting metformin, semaglutide initiation was lower in the poorest vs high-income neighbourhoods (aHR 0.86), despite a higher obesity burden. #2705 @Rheumnow #ACR26 https://t.co/uAzwdowufE

https://x.com/DrMiniDey/status/2120197542688219529/photo/1

In an updated systematic review and meta analysis for the GRAPPA treatment guidelines, men with PsA had higher odds of response than women across advanced therapies: ACR20 1.42, ACR50 1.74 and minimal disease activity 1.94. Placebo response did not differ by sex, odds ratio 1.00.

Pain is not always inflammation in RA. Among 283 pts starting/changing DMARDs, 4 phenotypes emerged. One had the highest pain, fatigue, poor sleep and distress despite only moderate inflammation and remained most symptomatic at 12 weeks. #ACR26 @RheumNow https://t.co/stcP70a4iZ

https://x.com/bella_mehta/status/2120194846929420548/photo/1

A new RA target? Modified scores excluding TJC & patient global identified more patients with low inflammatory activity, with similar/lower radiographic progression than conventional remission. Useful where comorbidities may influence assessments #2808 #ACR26 @Rheumnow #ACRBest https://t.co/GZUOBc3mKn

https://x.com/DrMiniDey/status/2120193013213438342/photo/1

RISE: Inflix -> Inflix Biosim Ab#2807 #ACR26 @RheumNow CDAI (n=~1500), RAPID3 (n=~3100) analysis Biosimilar infliximab equally effective in switched pts https://t.co/Ud6sZeJFhU

RA-ILD: The Warning Signs Are Already on CT 30% of patients with RA-ILD progressed within 2 years. Definite UIP and inspiratory mosaic attenuation independently predicted progression, reaching 70% when both were present. @RheumNow #ACR26 https://t.co/9MiPIOJFil

https://x.com/Mota_licia_reum/status/2120181499416985864/photo/1

The Usual Suspects: Unmasking Difficult-to-Treat RA #ACR26: IgA-MAA emerged as an independent predictor of D2T-RA, while adipokines showed predictive potential in patients with obesity. The clues may lie beyond clinical factors. @RheumNow https://t.co/g6TGguXggs

https://x.com/Mota_licia_reum/status/2120176208390553910/photo/1

Symptom-Inflammation Phenotypes in Active RA Data from CPIRA cohort (n=283, established active RA), used K-means clustering on PROs + inflammatory markers (SJC28, hsCRP) to find phenotypes. Identified 4 clusters: -C1 (n=117): low-moderate inflammation, low symptoms -C2 (n=77): https://t.co/s8wCEtj3iI

GDF-15: A New Signal for Heart Failure in RA #ACR26 Abstract #2431: In 2,212 RA patients, elevated GDF-15 predicted heart failure independently of traditional CV risk factors, but not atherosclerotic events. @RheumNow #ACR26 https://t.co/ridvwsHLGD

https://x.com/Mota_licia_reum/status/2120175101538607579/photo/1

Can respiratory infections trigger RA-ILD? #ACR26 Abstract 1737: Respiratory infections were associated with subsequent RA-ILD, particularly non-fibrotic disease. RSV showed a particularly strong association (OR 7.06). A potential environmental trigger. @RheumNow #ACR26 https://t.co/3TxiMYgjhO

https://x.com/Mota_licia_reum/status/2120174514927714563/photo/1

Lifestyle modification improved markers of lymphocyte aging & disease activity in 20 adults with RA. Pooled DAS28-CRP improved ~14% over 16 weeks. Immune measures did not differ significantly between exercise/weight-loss coaching and lifestyle counselling. #2803 @Rheumnow #ACR26

Therapeutic Updates

Make Rheum for Rads: Autoimmune ILD Diagnosis, Monitoring, and the Patient Experience

Sponsored by Boehringer Ingelheim Pharmaceuticals, Inc.

Aug 01, 2026

Drs. Elizabeth Volkmann and Robert Suh explore the roles rheumatologists and radiologists play in diagnosing and monitoring autoimmune ILD and hear from a patient about her experience.

Read Post

ACR 2026 Daily Podcasts - Day2c
Nov 10, 2026
ACR 2026 Daily Podcasts - Day2b
Nov 10, 2026
ACR 2026 Daily Podcasts - Day2a
Nov 10, 2026

Topics

Rheumatoid Arthritis

Therapeutic Updates

Make Rheum for Rads: Autoimmune ILD Diagnosis, Monitoring, and the Patient Experience

Poster Hall

Long-term Malignancy Risk, Including in Higher CV-Risk RA: a JAKi and TNFi

Daily Download

GLP-1 Receptor Agonists in Rheumatology

Podcasts

Topic Videos

Do you get our email newsletter?